Martin Lush has over 40 years’ experience in the pharmaceutical and healthcare industries with specialised knowledge of all aspects of development, validation, manufacture and supply of vaccines, advanced therapeutics, combination products and biotechnology medicines. He has held global leadership positions in manufacturing strategy and operations, quality assurance, supply chain and logistics, and business improvement/optimisation. Martin is a global thought leader on the challenges facing healthcare in the post-COVID era (digital medicine, modernisation of regulatory processes and governance, culture change and reshaping organisations to be more resilient). He has worked in over 50 countries and is an advisor to government agencies, investment institutions, health care foundations and industry C-suites.
Most recently Martin joined Ugur Sahin, co-founder of BioNTech, Kate Bingham, head of the UK’s vaccine taskforce and Seth Berkley, chief executive of Gavi global health alliance to discuss the COVID pandemic, vaccine hesitancy and manufacturing bottlenecks at the Financial Times Global Boardroom.
The debate is available to watch here.